IN THE UNITED STATES PATENT AND TRADEMARIXOFFICE

Title: Methods for Diagnosis and Treatment of MDK1 Signal Transduction Disorders

erial No.: 08/368,776

Group Art Unit: 1806

Filed: 1/3/95

Examiner: Scheiner

Inventors: Ciossek et al.

Atty. Docket No.: 208/007

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.56 and §1.97

Honorable Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent Office of all references coming to the attention of Applicants or attorneys or agents for Applicants which are or may be material to the examination of the subject application, Applicants' representatives hereby supplement any earlier submission of references and invite the Examiner's attention to the enclosed references listed on the accompanying revised PTO Form 1449 entitled "Supplemental List of References Cited".

Identification of references listed on PTO Form 1449 is not to be construed as an admission of Applicants or attorneys for Applicants that such references are available as "prior art" against the subject application. The right is reserved to antedate any item in accordance with standard procedure.

This submission is understood to complement the results of the Examiner's own independent search. The submission should not be construed as a representation that a comprehensive search was made, or that the cited items are inclusive of all the relevant and material citations that may be available publicly.

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Down W. Mahr

1300

Applicants' representatives hereby certify that no item of information contained in the "Supplemental List of References Cited" filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to our knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56 (c) more than 3 months prior to the filing of this Information Disclosure Statement. Reference AA is being cited in that it discloses HEK11, believed to be the human homologue of murine MDK1.

Applicants respectfully request that the Examiner review the foregoing references, as set forth in the Form PTO-1449, and that they be made of record in the file history of the above-captioned Application.

Respectfully submitted,

Dated: 7/1/96

Darlene W. Haves Reg. No.

David W. Maher

Reg. No.

SUGEN, Inc.

515 Galveston Drive

Redwood City, CA 94063-4720